AGC Biologics Manufactures Key Ingredient in Potential COVID-19 Treatment Drug, Leronlimab
AGC Biologics April 29, 2020 at 3:49 PM
The drug, Leronlimab, owned by CytoDyn, containing a special molecule manufactured by AGC Biologics, is showing favorable results in the treatment of severely affected COVID-19 patients. AGC Biologics stands ready to ramp up manufacturing to meet demand once this drug is FDA approved.
AGC Biologics to Manufacture LVV for CAR-T Therapy Approved by FDA for Autolus Therapeutics’ AUCATZYL®
December 11, 2024 at 9:00 AM
AGC Biologics Appoints Alberto Santagostino as new Chief Executive Officer
October 28, 2024 at 3:00 AM